James Plante

Thynk Capital was founded by entrepreneur, inventor and investor, Jim Plante.
Jim is currently the CEO, Founder and Chairman of Klotho Therapeutics (KTI) which is developing modified human Klotho protein/hormone for the prevention and treatment of kidney diseases and the major diseases of aging including cancer, diabetes, neuro-degenerative diseases, and human frailty.
www.KLOTHO.com Jim Plante is the Founder and former CEO of Pathway Genomics, as well as Chairman Emeritus.
His mission was to Democratize affordable genetic testing and enable access to this potentially lifesaving information.
As Co-Founder and CEO of E-Band Communications, Jim launched the industry’s first multi-gigabit capacity 70/80GHz band communications links for fiber optic replacement and mobile wireless infrastructure.
Starting in 2004, Jim was the founder, CEO and Chairman of SmartDrive Systems.
SmartDrive’s groundbreaking SAAS commercial vehicle safety program uses an integrated video, audio, GPS and sensor based platform to monitor a driver and vehicle in real time, as well as capture and coach unsafe driving habits, reducing the risk of accidents.
To date, the system has prevented 10,000 deaths and injuries, 50,000+ accidents, and eliminated over $2Billion in financial losses.
He was Appointed by the U.S.
Secretary of Commerce and U.S.
Trade Representative (USTR) to Industry Trade Advisory Committee which he served from 2015 through early 2018.
Jim started the Foundation for Kidney Transplant Research to affect public policy towards living kidney donation in order to proactively help to save the lives of 700,000 Americans in desperate need of a kidney transplant.
www.kidneyresearchfoundation.org Mr. Plante continues his commitment to innovation in the healthcare field through Thynk Capital, an early stage investment firm in biotechnology, healthcare and technology companies.